SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma’s arm hikes stake in Ranbaxy Malaysia

09 Jan 2018 Evaluate

Sun Pharmaceutical Industries’ one of the wholly owned subsidiaries has increased its shareholding in Ranbaxy Malaysia, Malaysia, by way of further purchase of 508,313 shares of face value of MYR 1.00 each (equivalent to 6.35%) of Ranbaxy Malaysia.

Ranbaxy Malaysia is a subsidiary of the company, and the total shareholding of Sun Pharmaceutical Industries along with its wholly owned subsidiary is 79.55%, prior to this purchase of shares.

Post completion of this purchase of shares, the total holding of the company along with its wholly owned subsidiary will increase from 79.55% to 85.90% in Ranbaxy Malaysia.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.


Sun Pharma Inds. Share Price

1847.30 12.90 (0.70%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×